Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford is one of 28 sites that will benefit from over £160 million awarded over five years to expand early phase clinical research for the benefit of NHS patients.

Doctor with a patient

The National Institute for Health Research (NIHR) has announced funding for its Clinical Research Facilities (CRF). The NIHR Oxford Clinical Research Facility is one of five new facilities and will be hosted by Oxford University Hospitals (OUH) NHS Foundation Trust. The Oxford Health Clinical Research Facility was also awarded funding.

CRFs support the delivery of early translational and experimental medicine research, from studies testing new treatments in patients for the very first time (first-in-human trials) through to early safety and efficacy trials (Phase II trials). They provide dedicated purpose-built facilities and expertise for the delivery of high-intensity studies funded by the NIHR, charities, the life sciences industry and other organisations.

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) based at the Churchill Hospital, will act as the hub of the Oxford CRF. It provides a resource for early phase, experimental research across the University of Oxford's Medical Sciences Division. The EMCRF is central to the clinical translational strategy of the Oxford Biomedical Research Centre (BRC), providing service to all specialities in the BRC Themes.

Professor Duncan Richards, Director of the NIHR Oxford CRF and the EMCRF, commented: "This is a welcome opportunity to become part of the NIHR CRF Network. It represents an important new resource to support clinical translation across the University's Medical Sciences Division.

"The new facilities and collaboration with other capabilities in Oxford enhances our ability to deliver a wider range of early phase studies for the benefit of patients. Training and developing a new generation of doctors, nurses and allied health professionals in early phase experimental medicine trials is also core to our mission and we welcome NIHR's support for this." 

Professor Helen McShane, Director of the NIHR Oxford BRC, said: "This announcement is very welcome, as it will allow Oxford to expand the early phase clinical trials we conduct – much of it with Oxford BRC funding – that can be translated into tangible life-changing benefits for NHS patients. We also see it as a great opportunity to develop the skills and experience of young researchers in carrying out early phase experimental medicine trials."

Read the full story on the Oxford NIHR Biomedical Research Centre website.

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.